William Berger1, Ellen Sher2, Sandra Gawchik3, Stanley Fineman4. 1. From the Allergy and Asthma Associates of Southern California, Mission Viejo, California, USA. 2. Atlantic Allergy, Asthma and Immunology Associates of New Jersey, Ocean, New Jersey, USA. 3. Asthma Allergy Associates, Glen Mills, Pennsylvania, USA. 4. Atlanta Allergy and Asthma Clinic, Marietta, Georgia, USA.
Abstract
BACKGROUND: The safety of a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) has been established in adults and adolescents with allergic rhinitis but not in children <12 years old. OBJECTIVE: To evaluate the safety and tolerability of an intranasal formulation of AZE and FP in children ages 4-11 years with allergic rhinitis. METHODS: The study was a randomized, 3-month, parallel-group, open-label design. Qualified patients were randomized in a 3:1 ratio to AZE/FP (n = 304) or fluticasone propionate (FP) (n = 101), one spray per nostril twice daily, and to one of three age groups: ≥4 to <6 years, ≥6 to <9 years, and ≥9 to <12 years. Safety was assessed by child- or caregiver-reported adverse events, nasal examinations, vital signs, and laboratory assessments. RESULTS: The incidence of treatment-related adverse events (TRAEs) was low in both the AZE/FP (16%) and FP-only (12%) groups after 90 days' continuous use. Epistaxis was the most frequently reported TRAE in both groups (AZE/FP, 9%; FP, 9%), followed by headache (AZE/FP, 3%; FP, 1%). All other TRAEs in the AZE/FP group were reported by ≤1% of the children. The majority of TRAEs were of mild intensity and resolved spontaneously. Results of nasal examinations showed an improvement over time in both groups, with no cases of mucosal ulceration or nasal septal perforation. There were no unusual or unexpected changes in laboratory parameters or vital signs. CONCLUSION: The intranasal formulation of AZE and FP was safe and well tolerated after 3 months' continuous use in children with allergic rhinitis.The study was registered on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT01794741).
RCT Entities:
BACKGROUND: The safety of a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) has been established in adults and adolescents with allergic rhinitis but not in children <12 years old. OBJECTIVE: To evaluate the safety and tolerability of an intranasal formulation of AZE and FP in children ages 4-11 years with allergic rhinitis. METHODS: The study was a randomized, 3-month, parallel-group, open-label design. Qualified patients were randomized in a 3:1 ratio to AZE/FP (n = 304) or fluticasone propionate (FP) (n = 101), one spray per nostril twice daily, and to one of three age groups: ≥4 to <6 years, ≥6 to <9 years, and ≥9 to <12 years. Safety was assessed by child- or caregiver-reported adverse events, nasal examinations, vital signs, and laboratory assessments. RESULTS: The incidence of treatment-related adverse events (TRAEs) was low in both the AZE/FP (16%) and FP-only (12%) groups after 90 days' continuous use. Epistaxis was the most frequently reported TRAE in both groups (AZE/FP, 9%; FP, 9%), followed by headache (AZE/FP, 3%; FP, 1%). All other TRAEs in the AZE/FP group were reported by ≤1% of the children. The majority of TRAEs were of mild intensity and resolved spontaneously. Results of nasal examinations showed an improvement over time in both groups, with no cases of mucosal ulceration or nasal septal perforation. There were no unusual or unexpected changes in laboratory parameters or vital signs. CONCLUSION: The intranasal formulation of AZE and FP was safe and well tolerated after 3 months' continuous use in children with allergic rhinitis.The study was registered on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT01794741).
Authors: D Price; S Shah; S Bhatia; C Bachert; W Berger; J Bousquet; W Carr; P Hellings; U Munzel; G Scadding; P Lieberman Journal: J Investig Allergol Clin Immunol Date: 2013 Impact factor: 4.333
Authors: Eli Meltzer; Paul Ratner; Claus Bachert; Warner Carr; William Berger; G Walter Canonica; James Hadley; Phil Lieberman; Frank C Hampel; Joaquim Mullol; Ullrich Munzel; David Price; Glenis Scadding; J Christian Virchow; Ulrich Wahn; Ruth Murray; Jean Bousquet Journal: Int Arch Allergy Immunol Date: 2013-05-04 Impact factor: 2.749
Authors: William Berger; Eli O Meltzer; Niran Amar; Adam T Fox; Jocelyne Just; Antonella Muraro; Antonio Nieto; Erkka Valovirta; Magnus Wickman; Jean Bousquet Journal: Pediatr Allergy Immunol Date: 2016-03 Impact factor: 6.377
Authors: William E Berger; Shailen Shah; Phil Lieberman; James Hadley; David Price; Ullrich Munzel; Sanjay Bhatia Journal: J Allergy Clin Immunol Pract Date: 2014-01-01
Authors: Robert A Nathan; Eli O Meltzer; Jennifer Derebery; Ulka B Campbell; Paul E Stang; Marlo A Corrao; Gina Allen; Richard Stanford Journal: Allergy Asthma Proc Date: 2008 Nov-Dec Impact factor: 2.587
Authors: William F Schoenwetter; Leon Dupclay; Sireesh Appajosyula; Marc F Botteman; Chris L Pashos Journal: Curr Med Res Opin Date: 2004-03 Impact factor: 2.580